Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by starrunneron Mar 22, 2015 8:24am
171 Views
Post# 23548206

RE:RE:RE:Systemic injection vs direct intra-tumor

RE:RE:RE:Systemic injection vs direct intra-tumorWow thats fantastic information your sharing with the board PatK. Nice to contribute to constructive discussion, eh?

I trust you have a source for this information and the timeline you report is rock solid. For you to comment on projected timelines you must have had them written in blood and notarized.


Lilge commented on intra-tumor injection when asked about treating larger extensive tumors. His comment was that TLT could treat the tumor via bladder instillation of TLD-1433 in possible combination with intratumor injection and possible surgical resection for extensive cases.

There really should be no reason that TLD-1433 could not be used IV. If Rutherin has an affinity for transferrin binding sites that are plentiful on cancerous tumors and Rutherin demonstrates non-toxicity to normal cells then we should be in the clear. The issue wil be around whether or not we can get the light to some of these tumors.

Toxicity will need to demonstrate that when delivered IV, that there is a reasonable time for the drug to clear the body and that it is excreted or metabolized and that there is no toxicity to other cells/organs.

THis will come with time, I am focused on he current proposed trial in bladder cancer. This is the shortest pathway to approval of this drug/technology. Once the SP reponds to positive results in human trials there will be plenty of cash/offers/partnerships to take this to the next level and another trading platform.

Runner
Bullboard Posts